Trial Profile
A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Long-Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Albiglutide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms HARMONY 4
- Sponsors GlaxoSmithKline; GSK
- 19 Jul 2019 As per European Clinical Trials Database record, trial is completed in UK (End Date: 8 Mar 2013).
- 16 Sep 2016 Results of post-hoc pooled analysis from HARMONY 1-7 trials assessing the relationship between renal function and change in HbA 1c, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
- 17 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.